Solid interim results
​First half results to 30th September demonstrate clear progress against the Board’s objective of creating a business with at least a £100m valuation by 2020. Proforma sales growth of 97%, driven by new customer contract wins and by pipeline progress from existing customers’ medical device programmes. The potential for operations in China (via joint venture) and the development of a new production facility for a global device manufacturer are both in late stage discussions which would underpin longer term growth, if successfully executed. The long term pipeline continues to build with strategic collaborations.
Collagen Solutions is a holding company. Through its subsidiaries, Co. is engaged in the supply, development and manufacture of medical-grade collagen components and biomaterials for use in regenerative medicine, medical devices and in-vitro diagnostics. Co.'s primary products include medical-grade collagen, the primary protein in those tissues that provides a supportive environment for the cells, and processed native tissues such as pericardium, a tissue that surrounds the heart, and medical-grade collagen formulations. Co. supplies these as standard raw materials as well as in custom formulations that are used for the basic research to regenerative medicine therapies and medical devices.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.